Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04345653 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04345653 is a Phase 2 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 48 participants.
The verdict
NCT04345653, a Phase 2 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVID-19) in high-risk, healthy acute care provider participants exposed, directly or indirectly, to COVID-19 patients. There is a more than 50 years track record of safety of HCQ for treatment and prevention of various disease states. Early data on use of HCQ for COVID treatment suggests anti-viral activity and immunomodulatory properties for reducing inflammation associated with COVID-19.
Interventions
- DRUG Hydroxychloroquine Sulfate (HCQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-04-14 |
| Est. Completion | 2021-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04345653
The ClinicalTrials.gov registry entry for NCT04345653 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine Sulfate (HCQ) is the first listed.
NCT04345653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04345653 about?
NCT04345653 is a clinical study titled "Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers". The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVI...
What is the current status of trial NCT04345653?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-04-14. Estimated completion is 2021-05-10.
What interventions are being tested in trial NCT04345653?
The interventions under investigation include: Hydroxychloroquine Sulfate (HCQ) (DRUG).
Who is sponsoring clinical trial NCT04345653?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.